Osama Alnahar

Therapeutic selective leukotriene b4 antagonism for human lymphedema

Despite a high prevalence and extensive morbidity, there are no approved pharmacological interventions for lymphedema. Selective inhibition of leukotriene B 4 has been identified as a potential therapeutic target to address the morbidity and symptomatology associated with lymphed...